Monday, March 03, 2008

Obesity drugs will keep global pharmaceutical firms' bottomlines bulging - S&P

Kudos, fatsos.
"Standard & Poor's (NYSE:MHP) Ratings Services said the current global market for prescription drugs to treat obesity-related illnesses, such as diabetes, cardiovascular disorders, hypertension, and high cholesterol is at about 70 bln usd but will double by 2020, assuming this market grows at a compound average of just 5 pct per year...

A World Health Organization(WHO) projection says that the number of adults overweight worldwide will rise to 2.3 bln by 2015 from 1.6 bln now, and that obesity levels will rise to 700 mln from 400 mln."
Thanks for doing what you can for Big Pharma.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.